



General description

INN	Methotrexate
ATC codes	L01BA01 L04AX03
Medicine type	Chemical agent
EML status history	<p>First added in 1977 (TRS 615) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Added in 1997 (TRS 882) for <b>Rheumatoid arthritis, serology unspecified</b></p> <p>Added in 2011 (TRS 965) for <b>Juvenile idiopathic arthritis</b></p> <p>Added in 2015 (TRS 994) for <b>Malignant neoplasms of breast</b></p> <p>Added in 2015 (TRS 994) for <b>Malignant trophoblastic neoplasms of placenta</b></p> <p>Added in 2015 (TRS 994) for <b>Osteosarcoma of bone and articular cartilage of unspecified sites</b></p> <p>Added in 2015 (TRS 994) for <b>Lymphoid leukaemia, not elsewhere classified</b></p> <p>Added in 2015 (TRS 994) for <b>Acute myeloid leukaemia with recurrent genetic abnormalities</b></p> <p>Removed in 2015 (TRS 994) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Added in 2021 (TRS 1035) for <b>Burkitt lymphoma including Burkitt leukaemia</b></p> <p>Added in 2023 (TRS 1049) for <b>Anaplastic large cell lymphoma, ALK-positive</b></p> <p>Added in 2023 (TRS 1049) for <b>Anaplastic large cell lymphoma, ALK-negative</b></p> <p>Added in 2023 (TRS 1049) for <b>Langerhans cell histiocytosis</b></p> <p>Added in 2023 (TRS 1049) for <b>Psoriasis of unspecified type</b></p> <p>Application rejected in 2023 (TRS 1049) for <b>Crohn disease site</b></p> <p>Application rejected in 2023 (TRS 1049) for <b>Psoriatic arthritis</b></p>
Wikipedia	<a href="#">Methotrexate</a> 
DrugBank	<a href="#">Methotrexate</a> 

Recommendations

**Section**    Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

**Indications**

Malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis

**Section**    Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

Rheumatoid arthritis, serology unspecified

**Section**    Medicines for juvenile joint diseases

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

Juvenile idiopathic arthritis

Section Dermatological medicines > Medicines affecting skin differentiation and proliferation

Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Indications

Psoriasis of unspecified type

Section Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

Crohn disease site

Psoriatic arthritis

